Brooks Laboratories Ltd
Brooks Laboratories Ltd (BROOKS) last reported results for the quarter ended Jun 2026, with sales of ₹22.96 crore and net profit of ₹-1.79 crore. The stock last traded at ₹58.8, a market capitalisation of ₹173 crore, on a P/E of 13.1. Over the past 52 weeks the stock has ranged between ₹36.3 and ₹132. Figures are as of 6 Oct 2026 and are not real time.
Brooks Laboratories Ltd share price and key metrics
- Current price
- ₹58.8
- Market cap
- ₹173 cr
- Stock P/E
- 13.1
- Book value
- ₹41.6
- ROE
- 22.0%
- ROCE
- 21.2%
- Dividend yield
- 0.00%
- 52w high / low
- 132/36.3
Metrics as of 6 Oct 2026. Not real time.
Track Brooks Laboratories Ltd
Cruxal reads every Brooks Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Brooks Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- 2%
- 3 Years
- 11%
- TTM
- -8%
- 10 Years
- %
- 5 Years
- 27%
- 3 Years
- 47%
- TTM
- 551%
- 10 Years
- -5%
- 5 Years
- -17%
- 3 Years
- -16%
- 1 Year
- -59%
- 10 Years
- %
- 5 Years
- -9%
- 3 Years
- -2%
- Last Year
- 22%
Brooks Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹22.96 cr, down 10.0% from ₹25.51 cr a year earlier. Net profit swung to a loss of ₹1.79 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| Expenses | 24.2 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.3 |
| Operating profit | -3.41 | -1.5 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 |
| OPM % | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% |
| Other income | 0.2 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 |
| Interest | 0.32 | 0.28 | 0.26 | 0.3 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| Profit before tax | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.5 | 1.53 | -1.79 |
| Tax % | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.5 | 1.52 | -1.79 |
| EPS (₹) | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Brooks Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 86 | 83 |
| Operating profit | 1 | -14 | -30 | -18 | -8 | 7 | 3 |
| OPM % | 0.7% | -16% | -47% | -22% | -10% | 8% | 3.1% |
| Net profit | -19 | -19 | -31 | -20 | -10 | 25 | 13 |
| EPS (₹) | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 8.34 | 4.49 |
TTM is the trailing twelve months to the most recent quarter.
Brooks Laboratories Ltd balance sheet
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 93 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 9 |
| Other liabilities | 52 | 83 | 29 | 19 | 18 | 17 |
| Total liabilities | 162 | 196 | 110 | 90 | 124 | 148 |
| Fixed assets | 108 | 110 | 15 | 14 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 92 |
| Other assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total assets | 162 | 196 | 110 | 90 | 124 | 148 |
As reported by the company. Total assets equal total liabilities by construction.
Brooks Laboratories Ltd cash flow
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 4 | -37 | -14 | -10 | 3 | 9 |
| Cash from investing | -5 | -25 | 0 | 0 | -45 | -3 |
| Cash from financing | 1 | 64 | 11 | 10 | 42 | 0 |
| Net cash flow | 0 | 2 | -3 | 0 | -0 | 7 |
| Free cash flow | -1 | -62 | -15 | -10 | 2 | 6 |
| CFO / operating profit | 1,519% | 261% | 48% | 56% | -26% | 131% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Brooks Laboratories Ltd operating ratios
| Per year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| ROCE % | — | -16% | -30% | -25% | -10% | 21% |
| Debtor days | 65 | 71 | 74 | 75 | 88 | 69 |
| Inventory days | 178 | 157 | 80 | 60 | 61 | 77 |
| Days payable | 233 | 159 | 165 | 97 | 90 | 80 |
| Cash conversion cycle | 9 | 68 | -12 | 38 | 59 | 66 |
| Working capital days | -85 | 34 | -37 | 34 | 43 | 34 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Brooks Laboratories Ltd shareholding pattern
Promoters held 52.62% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 10.38%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 63.59% | 59.06% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% |
| FIIs | 0.02% | 0.01% | 0.05% | 0.00% | 0.01% | 0.09% | 0.17% | 0.00% |
| DIIs | 3.86% | 3.86% | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% |
| Public | 32.53% | 37.08% | 36.95% | 37.00% | 37.00% | 36.91% | 36.84% | 37.00% |
| No. of shareholders | 11,282 | 10,521 | 10,537 | 10,317 | 10,078 | 10,532 | 10,741 | 11,161 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Brooks Laboratories Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached coverletter alongwith certificate under regulation 74(5).
Read the full analysis - Intimation of Closure of Trading Window.Insider Trading / SASTlow impact
- Brooks Laboratories Limited announces resignation of Company Secretary and Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Brooks Laboratories Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Brooks Laboratories Ltd announces newspaper publication regarding re-lodgement of transfer deedCompany Updatelow impact
Cruxal's analysis: Brooks Laboratories Ltd has published a notice in newspapers concerning the re-lodgement…
Read the full analysis - Brooks Laboratories Limited concludes 24th Annual General Meeting; shareholders review financial performance and approve key resolutionsAGM/EGMlow impact
Cruxal's analysis: Brooks Laboratories Limited held its 24th Annual General Meeting on 3rd September 2026…
Read the full analysis - Brooks Laboratories Ltd issues addendum to the notice of 24th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Brooks Laboratories has released an addendum to the notice for its 24th Annual General…
Read the full analysis - Brooks Laboratories Limited issues addendum to 24th AGM notice regarding related party transaction approvalsAGM/EGMlow impact
Cruxal's analysis: Brooks Laboratories Limited has issued an addendum to its 24th Annual General Meeting…
Read the full analysis - Brooks Laboratories issues addendum to 24th Annual General Meeting noticeOtherslow impact
Cruxal's analysis: Brooks Laboratories has released an addendum to the notice for its 24th Annual General…
Read the full analysis - Brooks Laboratories Ltd announces record date and e-voting schedule for upcoming corporate eventCorp. Actionlow impact
Cruxal's analysis: Brooks Laboratories has issued an intimation regarding the record date, book closure, and…
Read the full analysis - Brooks Laboratories Limited Reports Unaudited Financial Results for Quarter Ended 30th June 2026Company Updatelow impact
Cruxal's analysis: Brooks Laboratories Limited has released its unaudited standalone and consolidated…
Read the full analysis - Brooks Laboratories Reports Q1 FY27 Results: Standalone Profit at 1.42 crore, Consolidated Net Loss of 1.79 croreBoard Meetinghigh impact
Cruxal's analysis: Brooks Laboratories Limited reported standalone revenue from operations of 22.96 crore…
Read the full analysis - Brooks Laboratories Limited announces 24th Annual General Meeting scheduled for September 3, 2026Company Updatelow impact
Cruxal's analysis: Brooks Laboratories Limited has issued a formal intimation regarding its 24th Annual…
Read the full analysis - Brooks Laboratories Ltd releases Annual Report for FY 2025-26Company Updatelow impact
Cruxal's analysis: Brooks Laboratories Ltd has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Brooks Laboratories Limited Announces 24th Annual General Meeting for September 3, 2026AGM/EGMlow impact
Cruxal's analysis: Brooks Laboratories Limited has issued a notice for its 24th Annual General Meeting (AGM)…
Read the full analysis - Brooks Laboratories Limited Announces FY 2025-26 Financial Results and AGM NoticeOthershigh impact
Cruxal's analysis: Brooks Laboratories Limited reported a strong financial performance for FY 2025-26, with…
Read the full analysis - Brooks Laboratories Ltd announces 24th Annual General Meeting to be held via VC/OAVMCompany Updatelow impact
Cruxal's analysis: Brooks Laboratories Ltd has issued a newspaper advertisement intimating the convening of…
Read the full analysis - Brooks Laboratories Limited schedules Board Meeting for June 2026 quarterly financial resultsBoard Meetinglow impact
Cruxal's analysis: Brooks Laboratories Limited has formally intimated the stock exchanges regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.